

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KA	LPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 4177	7WC001145 AGE :	: 56 Years SEX : Female	ABHA NO :
DRAWN :	REC	CEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR :	DR. A M ANTO		CLIENT PATIENT ID :
Test Report Status	Preliminary	Results	Biological Reference Interval Units

MEDIWHEEL HEALTH CHECKUP ABOVE 40(F)TMT

TREADMILL TEST	
TREADMILL TEST	NOT DONE
DENTAL CHECK UP	
DENTAL CHECK UP	NOT DONE
OPTHAL	
OPTHAL	NOT DONE
PHYSICAL EXAMINATION	
PHYSICAL EXAMINATION	COMPLETED







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA			PATIENT ID : KALPF	1103674177
ACCESSION NO : 4177WC001145 AGE : 56 Y	ears SEX : Female		ABHA NO :	
DRAWN : RECEIVED :	11/03/2023 12:14		REPORTED : 13/03/2023 15:46	
REFERRING DOCTOR : DR. A M ANTO			CLIENT PATIENT ID :	
Test Report Status <u>Preliminary</u>	Results			Units
MEDIWHEEL HEALTH CHECKUP ABOVE 40(F)T	MT			
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN BUN/CREAT RATIO	6		Adult(<60 yrs) : 6 to 20	mg/dL
BUN/CREAT RATIO CREATININE, SERUM	9.5			
CREATININE GLUCOSE, POST-PRANDIAL, PLASMA	0.63		18 - 60 yrs : 0.6 - 1.1	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA	324	High	Diabetes Mellitus : > or = 200. Impaired Glucose tolerance/ Prediabetes : 140 - 199. Hypoglycemia : < 55.	mg/dL
LIPID PROFILE, SERUM				
CHOLESTEROL	100		Desirable : < 200 Borderline : 200-239 High : >or= 240	mg/dL
TRIGLYCERIDES	84		Normal : < 150 High : 150-199 Hypertriglyceridemia : 200-499 Very High : > 499	mg/dL
HDL CHOLESTEROL	42		General range : 40-60	mg/dL
DIRECT LDL CHOLESTEROL	51		Optimum : < 100 Above Optimum : 100-139 Borderline High : 130-159 High : 160-189 Very High : >or= 190	mg/dL
NON HDL CHOLESTEROL	58		Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	16.8		< or = 30.0	mg/dL
CHOL/HDL RATIO	2.4	Low	3.30 - 4.40	
LDL/HDL RATIO	1.2		0.5 - 3.0	







CLIENT CODE : CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS 'THOMAS INTERNATED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME	: KALPANA				PA	TIENT ID :	KALPF1103674177
ACCESSION NO :	4177WC001145	AGE: 56 Ye	ars SEX	: Female	ABHA NO :		
DRAWN :		RECEIVED :	11/03/202	3 12:14	REPORTED :	13/03/202	3 15:46
REFERRING DOCT	DR : DR. A M ANTO				CLIEN	F PATIENT ID	:
Test Report Stat	us <u>Preliminar</u>	¥	Result	S			Units

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

A.CAD with > 1 feature of high risk group				
B. CAD with > 1 feature of Very high risk §	group or recurrent ACS (within 1 year) despite LDL-C			
< or $=$ 50 mg/dl or polyvascular disease				
	major risk factors or evidence of end organ damage 3.			
Familial Homozygous Hypercholesterolemi	a			
	betes with 1 major risk factor or no evidence of end			
organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.				
Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid				
plaque				
2 major ASCVD risk factors				
0-1 major ASCVD risk factors				
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors				
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use				
2. Family history of premature ASCVD 4. High blood pressure				
	B. CAD with > 1 feature of Very high risk g < or = 50 mg/dl or polyvascular disease 1. Established ASCVD 2. Diabetes with 2 n Familial Homozygous Hypercholesterolemi 1. Three major ASCVD risk factors. 2. Dia organ damage. 3. CKD stage 3B or 4. 4. L Coronary Artery Calcium - CAC >300 AU. plaque 2 major ASCVD risk factors 0-1 major ASCVD risk factors erosclerotic cardiovascular disease) Risk Fa s in males and > or = 55 years in females			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 4177WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANTO)	CLIENT PATIENT ID :
Test Report Status Preliminal	ry Results	Units

Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	<80 (Optional goal <or 60)<="" =="" th=""><th>>OR = 50</th><th>>OR = 80</th></or>	>OR = 50	>OR = 80
Extreme Risk Group	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR=70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

BLOOD					
GLYCOSYLATED HEMOGLOBIN (HBA1C)	12.1	High	Non-diabetic level	: 4.0 - 5.6%. : < 5.7%. : >6.5%	%
			Glycemic control goa More stringent goal General goal : Less stringent goal	: < 6.5 %. : < 7%.	
			Glycemic targets in 0 If eGFR > 60 : < 7% If eGFR < 60 : 7 - 8	6.	
MEAN PLASMA GLUCOSE	300.6	High	< 116.0		mg/dL
LIVER FUNCTION TEST WITH GGT					
BILIRUBIN, TOTAL	0.59		General Range : < 1	1.1	mg/dL
BILIRUBIN, DIRECT	0.31		General Range : < 0	0.3	mg/dL
BILIRUBIN, INDIRECT	0.28		0.00 - 1.00		mg/dL
TOTAL PROTEIN	6.4		Ambulatory : 6.4 - 8 Recumbant : 6 - 7.8		g/dL
ALBUMIN	3.8		20-60yrs : 3.5 - 5.2	2	g/dL
GLOBULIN	2.6		2.0 - 4.1		g/dL
ALBUMIN/GLOBULIN RATIO	1.5		1.0 - 2.0		RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	10		Adults : < 33		U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	11		Adults : < 34		U/L
ALKALINE PHOSPHATASE	128		Adult(<60yrs) : 35 -	- 105	U/L







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

REFERRING DOCTOR : DR. A M ANTO

DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME	: KALPANA			PATIENT ID :	KALPF1103674177
ACCESSION NO :	4177WC001145	AGE : 56 Years	SEX : Female	ABHA NO :	
DRAWN :		RECEIVED : 11/03	3/2023 12:14	REPORTED : 13/03/20	023 15:46

DRAWN :

CLIENT PATIENT ID :

Test Report Status <u>Preliminary</u>	Results			Units	
GAMMA GLUTAMYL TRANSFERASE (GGT)	29		Adult (female) : < 40	U/L	
TOTAL PROTEIN, SERUM					
TOTAL PROTEIN	6.4		Ambulatory : 6.4 - 8.3 Recumbant : 6 - 7.8	g/dL	
URIC ACID, SERUM			Recumbant . 0 - 7.0		
URIC ACID	3.7		Adults : 2.4-5.7	mg/dL	
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD					
ABO GROUP METHOD : GEL CARD METHOD	TYPE B				
RH TYPE	POSITIVE				
BLOOD COUNTS,EDTA WHOLE BLOOD					
HEMOGLOBIN	13.9		12.0 - 15.0	g/dL	
RED BLOOD CELL COUNT	5.70	High	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL COUNT	9.38		4.0 - 10.0	thou/µL	
PLATELET COUNT	259		150 - 410	thou/µL	
RBC AND PLATELET INDICES					
HEMATOCRIT	42.8		36 - 46	%	
MEAN CORPUSCULAR VOL	75.0	Low	83 - 101	fL	
MEAN CORPUSCULAR HGB.	24.4	Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	32.6		31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH	12.3		11.6 - 14.0	%	
MENTZER INDEX	13.2				
MEAN PLATELET VOLUME	9.6		6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT					
SEGMENTED NEUTROPHILS	66		40 - 80	%	
LYMPHOCYTES	28		20 - 40	%	
MONOCYTES	04		2 - 10	%	
EOSINOPHILS	02		1 - 6	%	
BASOPHILS	00		< 1 - 2	%	
ABSOLUTE NEUTROPHIL COUNT	6.19		2.0 - 7.0	thou/µL	
ABSOLUTE LYMPHOCYTE COUNT	2.63		1 - 3	thou/µL	
ABSOLUTE MONOCYTE COUNT	0.38		0.20 - 1.00	thou/µL	
ABSOLUTE EOSINOPHIL COUNT	0.19		0.02 - 0.50	thou/µL	







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA		PATIENT ID :	KALPF1103674177		
ACCESSION NO : 4177WC001145 AG	GE : 56 Years SEX : Female	ABHA NO :			
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/202	23 15:46		
REFERRING DOCTOR: DR. A M ANTO CLIENT PATIENT ID :					
Test Report Status <u>Preliminary</u> Results Units					
NEUTROPHIL LYMPHOCYTE RATI ERYTHROCYTE SEDIMENTATION RAT BLOOD SEDIMENTATION RATE (ESR) SUGAR URINE - POST PRANDIAL	· · ·	High 0 - 20	mm at 1 hr		
SUGAR URINE - POST PRANDIAL CYTOLOGY - CS (PAP SMEAR)	_ DETECTED (++) RESULT PENDING	NOT DETECTED			
THYROID PANEL, SERUM					
ТЗ	124.28	Adult : 60-181	ng/dL		
Τ4	8.00	3.2 - 12.6	µg/dl		
TSH 3RD GENERATION	2.740	50-80 Yrs : 0.35 - 4.5	µIU/mL		







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME :	KALPANA			PA	TIENT ID :	KALPF1103674177
ACCESSION NO :	4177WC001145	AGE : 56 Years	SEX : Female	ABHA NO :		
DRAWN :		RECEIVED : 11	/03/2023 12:14	REPORTED :	13/03/202	3 15:46
REFERRING DOCTO	DR: DR. A M ANTO			CLIEN	T PATIENT ID	:
Test Report Stati	us <u>Preliminar</u>	¥	Results			Units

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

SUGAR URINE - FASTING

SUGAR URINE - FASTING PHYSICAL EXAMINATION, URINE

COLOR APPEARANCE DETECTED (+++)

NOT DETECTED

PALE YELLOW SLIGHTLY HAZY







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 4177WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANT	0	CLIENT PATIENT ID :
Test Report Status Prelimina	nry Results	Units

CHEMICAL EXAMINATION, URINE

5.0	4.7 - 7.5	
1.010	1.003 - 1.035	
NOT DETECTED	NOT DETECTED	
DETECTED (++)	NOT DETECTED	
NOT DETECTED	NOT DETECTED	
NOT DETECTED	NOT DETECTED	
NOT DETECTED	NOT DETECTED	
NORMAL	NORMAL	
NOT DETECTED	NOT DETECTED	
NOT DETECTED	NOT DETECTED	/HPF
3-5	0-5	/HPF
8-10	0-5	/HPF
NOT DETECTED		
NOT DETECTED		
DETECTED (FEW)	NOT DETECTED	
	1.010 NOT DETECTED DETECTED (++) NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED NOT DETECTED 3-5 8-10 NOT DETECTED NOT DETECTED NOT DETECTED	1.0101.003 - 1.035NOT DETECTEDNOT DETECTEDDETECTED (++)NOT DETECTEDNOT DETECTED3-50-58-100-5NOT DETECTEDNOT DETECTEDNOT DETECTEDNOT DETECTED







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA	PATIENT ID : KALPF1103674177	
ACCESSION NO : 4177WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANTO		CLIENT PATIENT ID :

Test Report Status <u>Preliminary</u> Results	Units
---	-------

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary		
	tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either		
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by		
	genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or		
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal		
	diseases		
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous		
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl		
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of		
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice		
Uric acid	arthritis		
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.		
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis		

GLUCOSE FASTING, FLUORIDE PLASMA

GLUCOSE, FASTING, PLASMA

269

High Diabetes Mellitus : > or = 126. mg/dL Impaired fasting Glucose/ Prediabetes : 101 - 125. Hypoglycemia : < 55.

PHYSICAL EXAMINATION,STOOL CHEMICAL EXAMINATION,STOOL MICROSCOPIC EXAMINATION,STOOL RESULT PENDING RESULT PENDING RESULT PENDING







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

0000100100		
PATIENT NAME : KALPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 4177WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANT	0	CLIENT PATIENT ID :

Test Report Status Preliminary

Results

Units







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : K	ALPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 412	77WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :		RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR :	DR. A M ANTO		CLIENT PATIENT ID :
Test Report Status	Preliminary	Results	Units

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION	
Pus cells	Pus in the stool is an indication of infection	
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis	
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.	
Charcot-Leyden crystal	Parasitic diseases.	
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.	
Frank blood	Bleeding in the rectum or colon.	
Occult blood	Occult blood indicates upper GI bleeding.	
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.	
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.	
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.	
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.	

ADDITIONAL STOOL TESTS :

- 1. <u>Stool Culture</u>:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Fecal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. <u>Fecal Occult Blood Test(FOBT)</u>: This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. <u>Clostridium Difficile Toxin Assay</u>: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- 6. Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel: 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA	PATIENT ID : KALPF1103674177	
ACCESSION NO : 4177WC001145 AC	GE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANTO		CLIENT PATIENT ID :
)

Units **Test Report Status** Results **Preliminary**

diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Interpretation(s)

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract

Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)

• Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''''''s disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel: 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KALPANA	PATIENT ID : KALPF1103674177	
ACCESSION NO : 4177WC001145	AGE : 56 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR : DR. A M ANT	0	CLIENT PATIENT ID :
(

Test Report Status <u>Preliminary</u> Results Units	Test Report Status	<u>Preliminary</u>	Results	Units
---	--------------------	--------------------	---------	-------

The test is performed by both forward as well as reverse grouping methods. BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe. By contrast, whe 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 EXTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT'S TEST SUGAR URINE - FASTING-METHOD: DIPSTICK/BENEDICT'S TEST

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical,

stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents. **NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.







MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS Room A1, Ground Floor, Sitaram Tejal, Opp.110KV Substation, Ashwini Junction TRICHUR, 680022 KERALA, INDIA Tel : 93334 93334 Email : customercare.ddrc@srl.in

PATIENT NAME : KA	LPANA		PATIENT ID : KALPF1103674177
ACCESSION NO : 417	7WC001145 AG	E : 56 Years SEX : Female	ABHA NO :
DRAWN :	R	RECEIVED : 11/03/2023 12:14	REPORTED : 13/03/2023 15:46
REFERRING DOCTOR :	DR. A M ANTO		CLIENT PATIENT ID :
Test Report Status	<u>Preliminary</u>	Results	Units

-	

MEDIWHEEL HEALTH CHECKUP ABOVE 40(F)TMT

ECG WITH REPORT REPORT COMPLETED MAMMOGRAPHY -BOTH REPORT NOT DONE USG ABDOMEN AND PELVIS REPORT NOT DONE CHEST X-RAY WITH REPORT

REPORT

NOT DONE

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

DR.HARI SHANKAR, MBBS MD (Reg No - TCMC:62092) HEAD - Biochemistry & Immunology



SREEDEVI MP LAB TECHNOLOGIST



MANJU SHAJI RADIOGRAPHER

	1.1	2
1	IHX	<
4	Nel Lit	
1		
01		

DR. SINDHU GEORGE QUALITY MANAGER



